Trastuzumab — sold under the brand name Herceptin — is one of the most important cancer drugs ever invented. Approved by the FDA in 1998, it transformed HER2-positive breast cancer from one of the worst breast cancer subtypes to one of the most treatable. It also proved that monoclonal antibodies, paired with a molecular biomarker, could deliver precision medicine in oncology.
This is the story of how that drug came to be, how it works, and how the next generation of HER2 antibody-drug conjugates — T-DM1 (Kadcyla) and Trastuzumab deruxtecan (Enhertu) — pushed the original idea even further. You can explore these molecules interactively in the Antibody Design Lab.
The HER2 problem
HER2 stands for human epidermal growth factor receptor 2. Its gene is called ERBB2. HER2 is a transmembrane receptor tyrosine kinase that normally helps healthy cells receive signals to grow, divide, and survive. In about 15 to 20 percent of breast cancers, the ERBB2 gene is amplified — sometimes there are 25 or even 50 copies of the gene in each cell, instead of the normal two.
Gene amplification leads to massive over-production of HER2 protein on the cell surface. With so many receptors, signaling fires constantly: HER2 dimerizes with itself or with HER3, activates downstream pathways like PI3K-AKT and MAPK, and tells the cell to grow and divide without restraint. HER2-positive breast cancer was historically among the most aggressive subtypes, with poor prognosis before targeted therapy.
The mouse antibody 4D5
In the late 1980s, scientists at Genentech and UCLA generated a panel of mouse antibodies against the extracellular domain of HER2. One clone, called 4D5, showed an unusual property: it not only bound HER2, it slowed the growth of HER2-amplified breast cancer cells in the dish. That was the lead candidate.
The problem was that 4D5 was a mouse antibody. Inject a mouse antibody into a human and the human immune system makes anti-mouse antibodies (HAMA), which both neutralize the drug and can cause serious side effects. To turn 4D5 into a real medicine, it had to be made human.
Humanization
Genentech's scientists, led by Paul Carter and others, used a technique called CDR grafting. They identified the six complementarity-determining regions (CDR-H1, H2, H3 and CDR-L1, L2, L3) of 4D5 — the loops that actually contact HER2 — and transplanted just those loops onto a human IgG1 framework. The framework residues that supported the loops were also adjusted so that the binding geometry was preserved.
The result was a humanized antibody that was about 95 percent human and 5 percent mouse, with all of the original 4D5 binding affinity for HER2 retained. That molecule became Trastuzumab.
Mechanism of action
Trastuzumab does several things at once, which is part of why it works so well:
1. Binds domain IV of HER2
Trastuzumab binds the membrane-proximal extracellular domain of HER2 (domain IV). This is a specific docking site that is distinct from where Pertuzumab binds (domain II). The two antibodies can be used together because they don't compete for the same epitope.
2. Receptor internalization
Antibody binding promotes endocytosis of the HER2 receptor. Fewer HER2 receptors on the cell surface means less downstream signaling.
3. Blocks ligand-independent dimerization
HER2-amplified cells don't need a ligand to dimerize and signal — the sheer density of receptors on the surface drives constitutive signaling. Trastuzumab interferes with this auto-dimerization, damping the constant growth signal.
4. Recruits ADCC
Because Trastuzumab is a human IgG1, its Fc region binds FcγRIIIa on natural killer cells. The NK cells release perforin and granzymes that kill the antibody-coated cancer cells. ADCC is now believed to be one of the most important mechanisms of action in patients.
Clinical impact
Trastuzumab was approved by the FDA in September 1998 for HER2-positive metastatic breast cancer. Subsequent trials showed that adding Trastuzumab to standard chemotherapy in the adjuvant setting (early-stage HER2-positive disease) cut the risk of recurrence in half. That changed practice almost overnight.
In the years since, HER2 testing has become a routine part of breast cancer pathology. The decision tree for HER2-positive patients now includes Trastuzumab plus chemotherapy in the adjuvant setting, dual blockade with Trastuzumab + Pertuzumab in the neoadjuvant and metastatic settings, and ADC options like T-DM1 and Enhertu when disease progresses.
The ADC evolution: T-DM1 (Kadcyla)
ImmunoGen and Genentech took the next step around 2008-2013 by bolting a small-molecule toxin to Trastuzumab. The toxin is DM1, a maytansine derivative that disrupts microtubules and is far too toxic to give as a free drug. The linker is a non-cleavable thioether (MCC), which means DM1 stays attached until the antibody is fully degraded inside the lysosome.
T-DM1 (ado-trastuzumab emtansine, brand Kadcyla) was approved in 2013. It uses the antibody to deliver the toxin specifically to HER2-positive cells: the antibody binds, gets internalized, and the lysosomal machinery digests the antibody to release the toxin warhead inside the cell. Compared to bare Trastuzumab, T-DM1 is much more potent against cells that have become resistant to first-line HER2 therapy.
Trastuzumab deruxtecan (Enhertu) and the HER2-low era
Daiichi Sankyo and AstraZeneca followed with Trastuzumab deruxtecan in 2019, and it has since become arguably the most impactful ADC ever developed. Three things make it different from T-DM1:
- Different payload. Deruxtecan (DXd) is a topoisomerase I inhibitor, not a microtubule inhibitor. Topo I inhibition kills cells by a different mechanism, which is useful when DM1 resistance has set in.
- Higher drug-to-antibody ratio. Each Trastuzumab carries about eight DXd molecules instead of three or four, delivering more payload per binding event.
- Bystander effect. Once DXd is released inside a HER2-positive cell, it can diffuse out and kill neighboring tumor cells that don't themselves express HER2. This makes Enhertu effective in HER2-low tumors, which traditional Trastuzumab cannot treat.
The DESTINY-Breast04 trial in 2022 showed that Enhertu produced large survival improvements in HER2-low metastatic breast cancer patients — a population that previously had no targeted option. That created an entirely new patient category and roughly doubled the eligible population.
What you can do in the Antibody Design Lab
The Antibody Design Lab includes pre-loaded workspaces for the full Trastuzumab family:
- Trastuzumab workspace — heavy and light chain sequences, the six CDR loops highlighted, ImmuneBuilder structure prediction, and AntiFold variant design
- Trastuzumab deruxtecan workspace — same antibody backbone with notes on the DXd payload, the drug-to-antibody ratio, and the bystander mechanism
Bottom line
Trastuzumab is the textbook case for precision oncology done right: a clear molecular biomarker, a humanized antibody designed against a specific epitope, multiple parallel mechanisms of action, and a clinical trial program that proved survival benefit in both early-stage and metastatic disease. The ADC follow-ons take the same antibody scaffold and use it as a guided missile, expanding the treatable population to HER2-low tumors that no one thought could be hit with a HER2-targeted drug.